Katherine Longardner
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Katherine Longardner has a total of 109 co-authors. Here are the top co-authors by number of shared publications:
- Irene Litvan
University of California San Diego (UCSD) La Jolla California USA
5 shared publications - Fatta B. Nahab
Neuron23 South San Francisco California USA
3 shared publications - Brenton A. Wright
Department of Neurosciences, Parkinson and Other Movement Disorders Center, University of California San Diego, CA, USA
2 shared publications Cat Liu
Skaggs School of Pharmacy and Pharmaceutical Sciences University of California San Diego La Jolla California USA
2 shared publications- Dietrich Haubenberger
Human Motor Control Section National Institute of Neurological Disorders and Stroke, National Institutes of Health Bethesda Maryland USA
2 shared publications Irene Litvan
Department of Neurosciences University of California San Diego La Jolla California USA
2 shared publications
Latest Publications
- 8 December 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (11) , e218740
Clinical Reasoning: A 33-Year-Old Man With Rapidly Progressive Ataxia
Immunocompromised patients presenting with subacute neurologic deficits pose a diagnostic challenge given the broad differential diagnosis including infections and autoimmune disorders. We describe...
- 8 December 2026
- Published by Wolters Kluwer Health in Neurology
- Vol. 107 (11) , e218740
Clinical Reasoning: A 33-Year-Old Man With Rapidly Progressive Ataxia
Immunocompromised patients presenting with subacute neurologic deficits pose a diagnostic challenge given the broad differential diagnosis including infections and autoimmune disorders. We describe...
- Open Access
- 16 November 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (11)
Visit‐to‐visit blood pressure variability and cognitive decline in the oldest‐old
INTRODUCTION: The oldest‐old (≥90 years) have a high burden of cognitive impairment, yet the role of blood pressure (BP) variability remains unclear. We examined whether visit‐to‐visit resting systolic BP variability (rSBPV) is associated with cognitive decline. METHODS: We analyzed The 90+ Study participants ( n = 647) without dementia at baseline who had ≥3 longitudinal BP and cognitive assessments. rSBPV was defined as the root mean square error from within‐participant regression of systolic BP on age and categorized as low, medium, or high. Multi‐state models estimated transitions between normal cognition, cognitive impairment, and dementia. RESULTS: Compared with medium rSBPV, high rSBPV was associated with higher hazards of transitioning from normal cognition to cognitive impairment (hazard ratio [HR] 1.36, 95% confidence interval [CI] 1.05–1.74), from normal cognition to dementia (HR 2.90, 95% CI 1.26–6.69), and from cognitive impairment to dementia (HR 1.44, 95% CI 1.06–1.96). DISCUSSION: Higher rSBPV is associated with greater cognitive decline in older adults.
- 16 November 2026
- Published by Wiley in Alzheimer's & Dementia
- Vol. 22 (11)
Open AccessVisit‐to‐visit blood pressure variability and cognitive decline in the oldest‐old
INTRODUCTION: The oldest‐old (≥90 years) have a high burden of cognitive impairment, yet the role of blood pressure (BP) variability remains unclear. We examined whether visit‐to‐visit resting systolic BP variability (rSBPV) is associated with cognitive decline. METHODS: We analyzed The 90+ Study participants ( n = 647) without dementia at baseline who had ≥3 longitudinal BP and cognitive assessments. rSBPV was defined as the root mean square error from within‐participant regression of systolic BP on age and categorized as low, medium, or high. Multi‐state models estimated transitions between normal cognition, cognitive impairment, and dementia. RESULTS: Compared with medium rSBPV, high rSBPV was associated with higher hazards of transitioning from normal cognition to cognitive impairment (hazard ratio [HR] 1.36, 95% confidence interval [CI] 1.05–1.74), from normal cognition to dementia (HR 2.90, 95% CI 1.26–6.69), and from cognitive impairment to dementia (HR 1.44, 95% CI 1.06–1.96). DISCUSSION: Higher rSBPV is associated with greater cognitive decline in older adults.
- Open Access
- 27 July 2026
- Published by Elsevier in Clinical Neurophysiology
- Vol. 191
Orthostatic hypotension and acute cognitive dysfunction in Parkinson’s disease: insights from functional near-infrared spectroscopy
- 27 July 2026
- Published by Elsevier in Clinical Neurophysiology
- Vol. 191
Open AccessOrthostatic hypotension and acute cognitive dysfunction in Parkinson’s disease: insights from functional near-infrared spectroscopy
- Open Access
- 8 May 2026
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 16, 30
Holmes Tremor in CADASIL Responsive to Multi-Targeting Deep Brain Stimulation (DBS): An Educational Case with Video and Electrophysiology
Background: Holmes tremor (HT) is a disabling condition, often resistant to medical therapy. Case report: A 51-year-old woman with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) presented with severe right upper limb HT unresponsive to multiple medications. She underwent deep brain stimulation (DBS) with dual-lead, triple-targeting of the left ventral intermediate nucleus (VIM), posterior subthalamic area (PSA), and globus pallidus interna (GPi) with improvement in tremor. Discussion: To our knowledge, this case represents the first reported instance of HT in CADASIL and highlights the potential of multi-target DBS for complex, treatment-refractory hyperkinetic movement disorders. Highlights We describe the first reported instance of Holmes tremor occurring as a manifestation of CADASIL, successfully treated with triple-target deep brain stimulation of the VIM, PSA, and GPi. This case demonstrates the potential of multi-target DBS to modulate complex motor networks in treatment-resistant tremor and enhance functional outcomes.
- 8 May 2026
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 16, 30
Open AccessHolmes Tremor in CADASIL Responsive to Multi-Targeting Deep Brain Stimulation (DBS): An Educational Case with Video and Electrophysiology
Background: Holmes tremor (HT) is a disabling condition, often resistant to medical therapy. Case report: A 51-year-old woman with cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL) presented with severe right upper limb HT unresponsive to multiple medications. She underwent deep brain stimulation (DBS) with dual-lead, triple-targeting of the left ventral intermediate nucleus (VIM), posterior subthalamic area (PSA), and globus pallidus interna (GPi) with improvement in tremor. Discussion: To our knowledge, this case represents the first reported instance of HT in CADASIL and highlights the potential of multi-target DBS for complex, treatment-refractory hyperkinetic movement disorders. Highlights We describe the first reported instance of Holmes tremor occurring as a manifestation of CADASIL, successfully treated with triple-target deep brain stimulation of the VIM, PSA, and GPi. This case demonstrates the potential of multi-target DBS to modulate complex motor networks in treatment-resistant tremor and enhance functional outcomes.
- 18 January 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (1) , e70106
Response to Comment on “Acute Pharmacodynamic Effects of Oral Levodopa on Blood Pressure in Parkinson’s Disease”
- 18 January 2026
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 46 (1) , e70106
Response to Comment on “Acute Pharmacodynamic Effects of Oral Levodopa on Blood Pressure in Parkinson’s Disease”
- 1 October 2025
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 45 (11) , 721-728
Acute Pharmacodynamic Effects of Oral Levodopa on Blood Pressure in Parkinson's Disease
Background: Levodopa decreases blood pressure (BP) in persons with Parkinson's disease (PwP), but no pharmacodynamic studies integrating systemic levodopa concentration measurements have characterized its hypotensive effects. Understanding this relationship is clinically relevant for guiding therapeutic decisions, such as how aggressively to treat hypotension before initiating or increasing levodopa. In this pilot study, we aimed to determine the acute pharmacodynamic effects of oral immediate‐release carbidopa/levodopa on BP in PwP. Methods: PwP taking chronic oral carbidopa/levodopa with baseline BP ≥ 90/60 mmHg were recruited. Participants withheld antiparkinsonian medications overnight prior to the study visit and received carbidopa/levodopa immediate‐release tablets at time 0. Capillary blood levodopa levels, seated BP measurements, and motor symptom assessments were performed at baseline and repeated every 10 min for 70–100 min. Non‐compartmental pharmacokinetic parameters of levodopa were determined, including the area under the curve up to the last time point (AUC 0 → last ), maximum concentration ( C max ), and time to maximum concentration ( T max ). Results: Fourteen PwP were enrolled (mean age 69.5 ± 7.6 years, six females). Two participants had orthostatic hypotension at baseline (defined as a sustained drop in systolic BP ≥ 20 mmHg or diastolic BP ≥ 10 mmHg within 3 min of standing), and six were taking antihypertensive medications. Mean arterial pressure (MAP) declined during the study from an average of 105 ± 13.1 mmHg at baseline to a nadir of 84 ± 15.8 mmHg. The maximum MAP drop occurred at 100 min post‐dose. Cumulative levodopa AUC negatively correlated with MAP (Pearson's r = −0.30; p = 0.00036). Conclusions: Oral levodopa is associated with acute hypotension in PwP, and levodopa exposure is inversely correlated with MAP. These effects should be considered when adjusting levodopa dosing, particularly in patients with hypotension, to improve safety outcomes.
- 1 October 2025
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 45 (11) , 721-728
Acute Pharmacodynamic Effects of Oral Levodopa on Blood Pressure in Parkinson's Disease
Background: Levodopa decreases blood pressure (BP) in persons with Parkinson's disease (PwP), but no pharmacodynamic studies integrating systemic levodopa concentration measurements have characterized its hypotensive effects. Understanding this relationship is clinically relevant for guiding therapeutic decisions, such as how aggressively to treat hypotension before initiating or increasing levodopa. In this pilot study, we aimed to determine the acute pharmacodynamic effects of oral immediate‐release carbidopa/levodopa on BP in PwP. Methods: PwP taking chronic oral carbidopa/levodopa with baseline BP ≥ 90/60 mmHg were recruited. Participants withheld antiparkinsonian medications overnight prior to the study visit and received carbidopa/levodopa immediate‐release tablets at time 0. Capillary blood levodopa levels, seated BP measurements, and motor symptom assessments were performed at baseline and repeated every 10 min for 70–100 min. Non‐compartmental pharmacokinetic parameters of levodopa were determined, including the area under the curve up to the last time point (AUC 0 → last ), maximum concentration ( C max ), and time to maximum concentration ( T max ). Results: Fourteen PwP were enrolled (mean age 69.5 ± 7.6 years, six females). Two participants had orthostatic hypotension at baseline (defined as a sustained drop in systolic BP ≥ 20 mmHg or diastolic BP ≥ 10 mmHg within 3 min of standing), and six were taking antihypertensive medications. Mean arterial pressure (MAP) declined during the study from an average of 105 ± 13.1 mmHg at baseline to a nadir of 84 ± 15.8 mmHg. The maximum MAP drop occurred at 100 min post‐dose. Cumulative levodopa AUC negatively correlated with MAP (Pearson's r = −0.30; p = 0.00036). Conclusions: Oral levodopa is associated with acute hypotension in PwP, and levodopa exposure is inversely correlated with MAP. These effects should be considered when adjusting levodopa dosing, particularly in patients with hypotension, to improve safety outcomes.
- Open Access
- 12 June 2025
- Published by Elsevier in Clinical Neurophysiology Practice
- Vol. 10, 188-201
Impact of clinical neurophysiological assessment on diagnosis and management of tremor disorders
- 12 June 2025
- Published by Elsevier in Clinical Neurophysiology Practice
- Vol. 10, 188-201
Open AccessImpact of clinical neurophysiological assessment on diagnosis and management of tremor disorders
- Open Access
- 14 April 2025
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 15 (1) , 14
Double-Blind, Randomized, Placebo-Controlled, Crossover Study of Oral Cannabidiol and Tetrahydrocannabinol for Essential Tremor
Background: Essential tremor (ET) is characterized by often disabling action tremors. No pharmacological agent has been developed specifically for symptomatic treatment. Anecdotal reports describe tremor improvement with cannabis, but no evidence exists to support these claims. We conducted a phase Ib/II double-blind, placebo-controlled, crossover pilot trial in participants with ET to investigate tolerability, safety, and efficacy of Tilray TN-CT120 LM, an oral pharmaceutical-grade formulation containing tetrahydrocannabinol (THC) 5 mg and cannabidiol (CBD) 100 mg. Our objectives were to determine if short-term THC/CBD exposure improved tremor amplitude and was tolerated. Methods: Participants with ET were randomized (1:1) to receive either TN-CT120 LM or placebo. Dose titration, driven by tolerability, was attempted every 2–3 days to three capsules daily maximum. Participants remained on the highest tolerated dose for two weeks before returning to complete assessments. After completing the first arm, participants titrated off the agent, underwent a three-week washout, and then returned for the same procedures with the alternate compound. The primary endpoint was tremor amplitude change from baseline using digital spiral assessment. Secondary endpoints explored safety and tolerability. Results: Among thirteen participants screened, seven were eligible and enrolled. Five completed all visits; one withdrew following a serious adverse event, and another did not tolerate the lowest dose. Intent-to-treat analyses performed for six participants did not reveal significant effects on primary or secondary endpoints. Conclusions: This pilot trial did not detect any signals of efficacy of THC/CBD in ET. Although preliminary due to the small sample size, our data do not support anecdotal reports of cannabinoid effectiveness for ET. Highlights This double-blind, randomized, placebo-controlled efficacy and tolerability pilot trial did not detect any signals of efficacy of oral cannabidiol and tetrahydrocannabinol in reducing essential tremor amplitude using either digital outcome measures or clinical rating scales. The oral cannabinoids were well-tolerated by most (five out of seven) participants.
- 14 April 2025
- Published by Ubiquity Press, Ltd. in Tremor and Other Hyperkinetic Movements
- Vol. 15 (1) , 14
Open AccessDouble-Blind, Randomized, Placebo-Controlled, Crossover Study of Oral Cannabidiol and Tetrahydrocannabinol for Essential Tremor
Background: Essential tremor (ET) is characterized by often disabling action tremors. No pharmacological agent has been developed specifically for symptomatic treatment. Anecdotal reports describe tremor improvement with cannabis, but no evidence exists to support these claims. We conducted a phase Ib/II double-blind, placebo-controlled, crossover pilot trial in participants with ET to investigate tolerability, safety, and efficacy of Tilray TN-CT120 LM, an oral pharmaceutical-grade formulation containing tetrahydrocannabinol (THC) 5 mg and cannabidiol (CBD) 100 mg. Our objectives were to determine if short-term THC/CBD exposure improved tremor amplitude and was tolerated. Methods: Participants with ET were randomized (1:1) to receive either TN-CT120 LM or placebo. Dose titration, driven by tolerability, was attempted every 2–3 days to three capsules daily maximum. Participants remained on the highest tolerated dose for two weeks before returning to complete assessments. After completing the first arm, participants titrated off the agent, underwent a three-week washout, and then returned for the same procedures with the alternate compound. The primary endpoint was tremor amplitude change from baseline using digital spiral assessment. Secondary endpoints explored safety and tolerability. Results: Among thirteen participants screened, seven were eligible and enrolled. Five completed all visits; one withdrew following a serious adverse event, and another did not tolerate the lowest dose. Intent-to-treat analyses performed for six participants did not reveal significant effects on primary or secondary endpoints. Conclusions: This pilot trial did not detect any signals of efficacy of THC/CBD in ET. Although preliminary due to the small sample size, our data do not support anecdotal reports of cannabinoid effectiveness for ET. Highlights This double-blind, randomized, placebo-controlled efficacy and tolerability pilot trial did not detect any signals of efficacy of oral cannabidiol and tetrahydrocannabinol in reducing essential tremor amplitude using either digital outcome measures or clinical rating scales. The oral cannabinoids were well-tolerated by most (five out of seven) participants.
- Open Access
- 8 March 2025
- Published by Elsevier in Autonomic Neuroscience
- Vol. 259, 103258
Interoception in Parkinson's disease: A narrative review and framework for translational research
- 8 March 2025
- Published by Elsevier in Autonomic Neuroscience
- Vol. 259, 103258
Open AccessInteroception in Parkinson's disease: A narrative review and framework for translational research